GLP-1 analogue could be an alternative to bariatric surgery

The uncertain quest for a safe and effective drug to achieve long term weight loss has taken a promising step forward with results from a one year clinical trial of the glucagon-like peptide-1 (GLP-1) analogue semaglutide. Obese people who received once-weekly subcutaneous of semaglutide achieved an average 12% loss in body weight over 68 weeks ...

Already a member?

Login to keep reading.

© 2021 the limbic